Literature DB >> 35646430

Ribociclib-induced Vitiligo: a Case Report.

Nicolás Silvestre Torner1, Antonio Aguilar Martínez1, María José Echarri González2, Sergio Tabbara Carrascosa1, Jorge Román Sainz1, Fernando Gruber Velasco1.   

Abstract

Entities:  

Keywords:  adverse event; breast cancer; ribociclib; selective cyclin-dependent kinase 4/6 inhibitors; vitiligo

Year:  2022        PMID： 35646430      PMCID： PMC9116537          DOI： 10.5826/dpc.1202a45

Source DB:  PubMed          Journal:  Dermatol Pract Concept        ISSN： 2160-9381


× No keyword cloud information.
  2 in total

Review 1.  Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.

Authors:  Kaitlin Rascon; Goran Flajc; Carmine De Angelis; Xinli Liu; Meghana V Trivedi; Ekim Ekinci
Journal:  Ann Pharmacother       Date:  2018-12-07       Impact factor: 3.154

2.  Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors.

Authors:  Pietro Sollena; Vasiliki Nikolaou; Nikolaos Soupos; Elias Kotteas; Dimitra Voudouri; Alexandros J Stratigos; Davide Fattore; Maria Carmela Annunziata; Armando Orlandi; Lucia Di Nardo; Zoe Apalla; Florian Deilhes; Maria Concetta Romano; Gabriella Fabbrocini; Vincent Sibaud; Ketty Peris
Journal:  Breast Cancer Res Treat       Date:  2020-09-10       Impact factor: 4.872
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.